Project Grant F32CA298459
Award Date 1/16/26
Completion Date 7/31/28
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $170,641 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The purpose of this 2-year award, which runs from August 1, 2025 to July 31, 2027, is to advance the understanding of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers. The research aims to identify immunologically distinct subsets of mismatch-repair proficient...
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $170,640 to the Dana-Farber Cancer Institute in Massachusetts to support research into the role of histone cleavage in breast cancer. The project aims to investigate how the histone demethylase KDM4C drives tumor growth in triple-negative breast cancer, a subtype with high treatment resistance and metastasis risk. Key objectives include determining if KDM4C prevents proteolytic...
- The National Cancer Institute awarded a $134,274 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Tufts University School of Medicine in Boston, MA. The goal of this 3.5-year project, starting December 1, 2024 and ending June 30, 2028, is to investigate the role of the TRPV1 ion channel in driving increased sensory nerve innervation within triple-negative breast cancer (TNBC) tumors. The research aims to uncover the mechanism by which TNBC cells stimulate...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- This $135,993 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Duke University to investigate the role of the ABL kinase-regulated HIF-1α-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The goal is to evaluate whether ABL-dependent activation of HIF-1 and TAZ leads to enhanced expression of unique transcriptional targets that promote brain metastasis in TNBC, and whether...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Colorado-Denver to study the role of the EYA3/PP2A protein complex in regulating the metastatic spread of triple-negative breast cancer (TNBC). The $647,118 award, effective March 1, 2025 through February 28, 2030, supports research aimed at understanding how EYA3 and its interaction with the B55A subunit of PP2A contribute to TNBC metastasis. The project...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....